Cabazitaxel in patients with refractory recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Results of phase II trial unicancer ORL03

Autor:	Karine Buffard, Carine Bellera, Christophe Le Tourneau, Joël Guigay, M. Degardin, Frederic Peyrade, Florence Orlandini, Jérôme Fayette
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Palliative care business.industry stomatognathic diseases Refractory Cabazitaxel Internal medicine medicine Methotrexate Basal cell In patient Head and neck business medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:e17028-e17028
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.e17028
Popis:	e17028 Background: After failure of platinum, anti-EGFR and taxanes R/M SCCHN patients (pts) are considered ‘refractory’ and methotrexate is the only option as palliative care. Cabatizaxel prolongs...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c2f00b0940444a7c3c84107921dc2f7f https://doi.org/10.1200/jco.2014.32.15_suppl.e17028 Zobrazit plný text záznamu